"Companion diagnostics": has their time come and gone?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25059519.
- Also identified by DOI 10.1158/1078-0432.CCR-14-0932 and PMC identifier 4155019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Proto-Oncogene Proteins c-met
- Quinazolines